Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Spotlight

GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines

Business

Deals
Earnings
Manufacturing

Policy & Regulation

Regulatory Landscape
Drug Pricing
IP & Litigation

Tools & Trackers

What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings

Conference Coverage

Partner Insights

Generics Bulletin Perspectives

Exploring market-shifting topics for the off-patent sector.

Generics Bulletin

Medtech Insight

Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development

Jun 28 2017

• By Sue Sutter

Syringes stuck in a dartboard

Related Content

FDA Priority Review For Some Generics Urged To Address 'Market Failure'

Dec 09 2015

BLAs More Appealing As 'Transition' NDAs, ANDAs Set To Lose Exclusivity

Mar 21 2016

Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting

May 26 2017

FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear

May 23 2016

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Oct 26 2016

FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting

Jun 22 2017

Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions

Jun 08 2017

Related Companies

Roche Holding AG

Vyera Pharmaceuticals, LLC

Ferring Pharmaceuticals

Actelion Pharmaceuticals Ltd.

Additional Topics

United States Generic Drugs Drug Approval Standards Pricing Debate Regulation BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
AdvertiseOpens in new window
Contact Us

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Generics Top 50 Ranking
Biosimilars
Generics
Value Added Medicines

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window